

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (previously presented) Modified TNF, comprising TNF covalently bound to PEG molecules having an approximate weight average molecular weight in the range of 15,000 to about 40,000.
2. (previously presented) The modified TNF of Claim 1 wherein said PEG is covalently bound to primary amine groups on said TNF through a biocompatible linker and where said PEG has an approximate weight average molecular weight in the range of 20,000 to about 30,000.
3. (previously presented) The modified TNF of claim 24 wherein said linker is selected from the group consisting of succinimidyl succinate, succinimidyl propionate, and N-hydroxy succinimidyl.
4. (original) The modified TNF of Claim 2 wherein said linker is selected from the group consisting of succinimidyl succinate, succinimidyl propionate, and N-hydroxy succinimidyl.
5. (original) The modified TNF of Claim 1 wherein said TNF is TNF- $\alpha$ .
6. (original) The modified TNF of Claim 1 wherein said TNF is isolated human TNF.

7. (original) The modified TNF of Claim 1 wherein said TNF is recombinant human TNF.

8. (original) The modified TNF of Claim 1 wherein said TNF is human TNF mutated by deleting amino acids 1-9 of the mature TNF protein.

9-13. (canceled)

14. (previously presented) A method of enhancing the circulating half life of TNF while reducing its toxicity comprising modifying said TNF by covalently bonding to it PEG molecules having an approximate weight average molecular weight in the range of 15,000 to about 40,000.

15. (previously presented) The method of Claim 14 in which said PEG is covalently bound to primary amine groups on said TNF through a biocompatible linker and where said PEG has an approximate weight average molecular weight in the range of 20,000 to about 30,000.

16. (previously presented) A method of enhancing the tumoricidal activity of TNF comprising modifying said TNF by covalently bonding to it PEG molecules each molecule having an approximate molecular weight of 20,000 to 30,000.

**DOCKET NO.:** PHOE-0057  
**Application No.:** 09/504,280  
**Office Action Dated:** February 3, 2004

**PATENT  
REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 CFR § 1.116**

17. (previously presented) The method of Claim 16 in which said PEG is covalently bound to primary amine groups on said TNF through a biocompatible linker and where said PEG has an approximate weight average molecular weight in the range of 20,000 to 30,000.

18-23. (canceled)

24. (previously presented) The modified TNF of claim 1 wherein said PEG is covalently bound to primary amine groups on said TNF through a biocompatible linker.